Preeclampsia is characterized by persistent high blood pressure and signs of liver or kidney damage that can affect pregnant women usually in the second half of pregnancy. It can also occur in women after the baby is delivered, mostly within 48 hours. Preelampsia occurs in around 2-8% of all pregnancies worldwide and is considered as a major cause of maternal and fetal mortality (1,2). It is responsible for over 70 000 maternal deaths and 500 000 fetal deaths worldwide every year (2). The cause of preeclampsia is still under debate and the clinical symptoms appear late during pregnancy (3). Early diagnosis is essential to prevent morbidity and mortality that is associated with preeclampsia (4).
Endostatin – a potential biomarker for early prediction of preeclampsia
Endostatin is one of the most potent inhibitors of angiogenesis as it specifically inhibits the proliferation and migration of endothelial cells. Endostatin is a degradation product of collagen XVIII, a protein of the extracellular matrix (ECM) which is expressed in the basement membranes. Endostatin is a stable analyte that can reliably be measured in human blood and urine samples.
Biochemical markers may be useful to predict preeclampsia early, prior to the onset of clinical signs. A recent study explored the potential use of the protein biomarker Endostatin for the early prediction of preeclampsia (5).
BIOMEDICA human ENDOSTATIN ELISA │BI-20742
- RELIABLE – validated according to FDA/ICH/EMEA guidelines
- FLEXIBLE – only ELISA that can measure human Endostatin in serum, plasma and urine
- OPTIMIZED for clinical samples – wide dynamic range
- TRUSTED – cited and sample values provided
- EFFICIENT – 20µl sample/well; results in 4.5 hours
BIOMEDICA mouse/rat ENDOSTATIN ELISA │BI-20742MR
- Fully validated for pre-clinical research (click here)
- Control included
Example of a BIOMEDICA ELISA assay kit
Literature
- Preeclampsia diagnosis and management. Best Pract Res Clin Anaesthesiol. Overton E, Tobes D, Lee A. 2022 May;36(1):107-121. doi: 10.1016/j.bpa.2022.02.003. Epub 2022 Feb 10. PMID: 35659948.
- Preeclampsia: Pathophysiology, Challenges, and Perspectives. Rana S, Lemoine E, Granger JP, Karumanchi SA. Circ Res. 2019 Mar 29;124(7):1094-1112. doi: 10.1161/CIRCRESAHA.118.313276. Erratum in: Circ Res. 2020 Jan 3;126(1):e8. PMID: 30920918.
- The placenta and preeclampsia: villain or victim? Melchiorre K, Giorgione V, Thilaganathan B. Am J Obstet Gynecol. 2022 Feb;226(2S):S954-S962. doi: 10.1016/j.ajog.2020.10.024. Epub 2021 Mar 24. PMID: 33771361.
- Early Detection of Preeclampsia Using Circulating Small non-coding RNA. Yoffe L, Gilam A, Yaron O, Polsky A, Farberov L, Syngelaki A, Nicolaides K, Hod M, Shomron N. Sci Rep. 2018 Feb 21;8(1):3401. doi: 10.1038/s41598-018-21604-6. PMID: 29467498; PMCID: PMC5821867.
- Endostatin and Cystatin C as Potential Biomarkers for Early Prediction of Preeclampsia. Alshannag F, Zaki RMM, Hemida E, ElBakry MMM, Noureldeen AFH. ACS Omega. 2023 Nov 1;8(45):42776-42786. doi: 10.1021/acsomega.3c05586. PMID: 38024766; PMCID: PMC10652833.
Citations
- Endostatin Is an Independent Risk Factor of Graft Loss after Kidney Transplant. Chu C, Hasan AA, Gaballa MMS, Zeng S, Xiong Y, Elitok S, Krämer BK, Hocher B. Am J Nephrol. 2020;51(5):373-380. doi: 10.1159/000507824. Epub 2020 Apr 22. PMID: 32320989.
- Validation of an enzyme-linked immunosorbent assay (ELISA) for quantification of endostatin levels in mice as a biomarker of developing glomerulonephritis. Wallwitz J, Aigner P, Gadermaier E, Bauer E, Casanova E, Bauer A, Stoiber D. PLoS One. 2019 Aug 12;14(8):e0220935. doi: 10.1371/journal.pone.0220935. PMID: 31404120; PMCID: PMC6690585.
- Higher Parathyroid Hormone Level Is Associated With Increased Arterial Stiffness in Type 1 Diabetes. Zobel EH, Theilade S, von Scholten BJ, Persson F, Tarnow L, Lajer M, Hansen TW, Rossing P. Diabetes Care. 2017 Mar;40(3):e32-e33. doi: 10.2337/dc16-2428. Epub 2017 Jan 6. PMID: 28062524.
- Endostatin in chronic kidney disease: Associations with inflammation, vascular abnormalities, cardiovascular events and survival. Kanbay M, Afsar B, Siriopol D, Unal HU, Karaman M, Saglam M, Gezer M, Taş A, Eyileten T, Guler AK, Aydin İ, Oguz Y, Tarim K, Covic A, Yilmaz MI. Eur J Intern Med. 2016 Sep;33:81-7. doi: 10.1016/j.ejim.2016.06.033. Epub 2016 Jul 7. PMID: 27394925.
Blood and urine biomarkers are tools to detect diseases, discover drugs and monitor patients. Biomarker research has identified Endostatin and Vanin-1 as promising novel markers to detect microvascular tissue injuries and renal tubular damage in drug-induced acute kidney injury, respectively. These and other proteins e.g. FGF23 and Periostin can easily be detected by ELISA. Check out our assay portfolio for clinical and preclinical research – novel biomarkers in clinical nephrology: www.bmgrp.com.
Assay Highlights:
• EASY – ready to use calibrators & controls included
• RELIABLE – validated according to international quality guidelines
• WIDELY CITED +1500 publications
Biomarkers in Clinical Nephrology – FGF23 ∙ Endostatin ∙ Periostin ∙ Vanin-1
ELISA kits developed and manufactured by BIOMEDICA
Check out our comprehensive brochure: Biomarkers for Clinical Nephrology link
Related Publications:
ENDOSTATIN FOR THE DETECTION OF ADVANCED MICROVASCULAR KIDNEY DAMAGE AND THE PROGRESSION OF KIDNEY DISEASE
Plasma endostatin predicts kidney outcomes in patients with type 2 diabetes. Chauhan K et al., Kidney Int, 2019; 95(2):439-446. Link. “Plasma endostatin was strongly associated with kidney outcomes in type 2 diabetics with preserved eGFR and improved risk discrimination over traditional predictors.”
The association between endostatin and kidney disease and mortality in patients with type 2 diabetes. Carlsson et al., Diabetes Metab, 2016; 42(5):351-357. Link. “In patients with T2D, circulating endostatin levels can predict the progression of kidney disease and mortality independently of established kidney disease markers.”
Endostatin in chronic kidney disease: Associations with inflammation, vascular abnormalities, cardiovascular events and survival. Kanbay et al., Eur J Intern Med, 2016; 33:81-87. Link. “Endostatin levels are independently associated with incident CVE in CKD patients.”
Elevated plasma levels of endostatin are associated with chronic kidney disease. Chen et al., Am J Nephrol, 2012; 35(4):335-340. Link. “These data indicate that elevated plasma endostatin is strongly and independently associated with CKD.”
VANIN-1 A MARKER FOR DRUG-INDUCED & SPONTANEOUS ACUTE KIDNEY INJURY AND OBSTRUCTIVE & DIABETIC NEPHROPATHY
Urinary vanin-1 associated with chronic kidney disease in hypertensive patients: A pilot study. Hosohata K et al., J Clin Hypertens (Greenwich). 2020 Aug;22(8):1458-1465. Link. “ .. urinary vanin-1 is associated with lower eGFR and higher UPCR and UACR, and might be a potential marker of decreased kidney function in hypertensive patients.”
A Novel Biomarker for Acute Kidney Injury, Vanin-1, for Obstructive Nephropathy: A Prospective Cohort Pilot Study. Washino et al., Int J Mol Sci, 2019; 20(4). Link. “Urinary Vanin-1 is a useful biomarker to detect and monitor the clinical course of obstructive nephropathy.”
Urinary Vanin-1 as a Novel Biomarker for Early Detection of Drug-Induced Acute Kidney Injury. Hosohata et al., J Pharm Exp Ther, 2002; 341(3):656–662. Link. “… compared with urinary Kim-1 and NGAL, urinary vanin-1 is an earlier and equally sensitive biomarker for drug-induced AKI.”
Vanin-1: A Potential Biomarker for Nephrotoxicant-Induced Renal Injury. Hosohata et al., Toxicology, 2011; 290(1):82–88. Link. “These results suggest that vanin-1 is a useful and rapid biomarker for renal tubular injury induced by organic solvents.”
Early Detection of Renal Injury Using Urinary Vanin-1 in Rats with Experimental Colitis. Hosohata et al., J App Tox, 2014; 34(2):184–190. Link. “Compared with Kim-1 and MCP-1, vanin-1 might be an earlier biomarker for the detection of renal injury in rats with experimental colitis.”
Proteomic identification of vanin-1 as a marker of kidney damage in a rat model of type 1 diabetic nephropathy. Fugmann T et al., Kidney Int. 2011: ;80(3):272-81. Link
FGF23 FOR RISK PREDICTION IN CHRONIC RENAL INSUFFICIENCY AND TO DETERMINE CARDIOVASCULAR RISK IN CKD
Association of Fibroblast Growth Factor 23 with Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study. Mehta et al., JAMA Cardiology, 2016; 1(5):548-556. Link . “Elevated FGF23 is independently associated with prevalent and incident atrial fibrillation in patients with mild to severe CKD.”
Fibroblast growth factor 23 in patients with acute dyspnea: Data from the Akershus Cardiac Examination (ACE) 2 Study. Lyngbakkena et al., Clin Biochem, 2018; 52:41-47 . Link. “Circulating FGF23 concentrations provide incremental prognostic information to established risk indices in patients with acute dyspnea.”
FGF23 and vitamin D metabolism in chronic kidney disease – mineral bone disorder. Piec et al., Bone Abstracts, 2016; 5:P469. Link. “cFGF23 is raised in patients with CKD as a compensatory response to hyperphosphatemia or phosphate overload.”
Renal and Extrarenal Effects of Fibroblast Growth Factor 23. Vervloet, Nature Reviews, 2019; Nephrology 1(2):109–120. Link. “.. FGF23 is also a valuable biomarker as it predicts risk of a wide variety of clinical events, in particular heart failure.”
PERIOSTIN A BIOMARKER FOR SEVERITY, PROGRESSION AND RESPONSE TO THERAPY IN HUMAN KIDNEY DISEASE ASSOCIATED TO HYPERTENSION
Identification of periostin as a critical marker of progression/reversal of hypertensive nephropathy. Guerrot et al., PLoS One, 2012; 7(3):e31974. Link. “… the results identify Periostin as a previously unrecognized marker associated with hypertensive nephropathy.”
Periostin Induces Kidney Fibrosis after Acute Kidney Injury via the p38 MAPK Pathway. An et al., Am J Physiol Renal Physiol, 2019; 316(3):F426-F437. Link. “Periostin promotes kidney fibrosis via the p38 MAPK pathway following acute kidney injury triggered by a hypoxic or ischemic insult. Periostin ablation may protect against chronic kidney disease progression”.
Periostin as a tissue and urinary biomarker of renal injury in type 2 diabetes mellitus. Satirapoj et al., PLoS One, 2015; 17; 10(4):e0124055. Link. “Urinary periostin is an associated renal derangement in patients with established diabetic nephropathy and it may be used as an early marker of diabetic renal injury.”
Urinary Periostin Excretion Predicts Renal Outcome in IgA Nephropathy. Hwang et al., Am J Nephrol, 2016; 44(6):481-492. Link. “POSTN/Cr value at initial diagnosis correlated with renal fibrosis and predicted the renal outcomes in patients with IgAN. It could be a promising urinary biomarker for renal fibrosis.”
Effects of periostin deficiency on kidney aging and lipid metabolism. An JN Aging (Albany NY). 2021. 13(19):22649-22665. Link.
Periostin in the Kidney. Wallace DP. Adv Exp Med Biol. 2019;1132:99-112. Link.
The research status and prospect of Periostin in chronic kidney disease. Jia YY, Yu Y, Li HJ. Ren Fail. 2020 Nov;42(1):1166-1172. Link.
Polycystic Kidney Disease and Renal Fibrosis. Xue C, Mei CL. Adv Exp Med Biol. 2019;1165:81-100. Link.
Periostin Promotes Cell Proliferation and Macrophage Polarization to Drive Repair after AKI. Kormann R J Am Soc Nephrol. 2020; 31(1):85-100. Link.
Kidney Injury Molecule-1 and Periostin Urinary Excretion and Tissue Expression Levels and Association with Glomerular Disease Outcomes. Wu Q Glomerular Dis. 2021 Jun;1(2):45-59. doi: 10.1159/000513166. Epub 2021. Link.
SCLEROSTIN FOR THE DIAGNOSIS OF HIGH BONE TURNOVER IN CKD AND THE PREDICTION OF CORONARY ARTERY CALCIFICATION
Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD. Behets et al., PLOS ONE, 2017; 12(5). Link. “Sclerostin, as opposed to DKK1, may qualify as a biomarker of CKD-MBD, particularly in dialysis patients.”
Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Cejka et al., Nephrol Dial Transplant, 2012; 27:226-230. Link. “Dialysis patients had significantly higher Sclerostin levels than controls.”
Serum Sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients. Kanbay et al., J Clin Endocrinol, 2014; 99(10):E1854–E1861. Link. “Serum sclerostin values are associated, even after multiple adjustments, with fatal and nonfatal cardiovascular events in a nondialyzed CKD population.”
Relationship between plasma levels of sclerostin, calcium–phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients. Pietrzyk et al., Int Urol Nephrol, 2019; 51(3):519-526. Link. “Increased circulating sclerostin levels seem to reflect slower bone turnover in HD patients. Low levels of sclerostin are associated with vitamin D deficiency and good phosphates alignment.”
Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it! Brandenburg VM et al., Nephrol Dial Transplant, 2019; ;34(3):408-414. Link
Chronic kidney disease is common in patients with heart failure and is associated with high mortality and morbidity. Biomarkers are needed that can accurately predict disease progression. Recent studies have provided evidence that circulating ENDOSTATIN increases significantly in patients with kidney and heart failure and may also contribute to disease progression. Learn more in this latest published review: “Endostatin in Renal and Cardiovascular Diseases” full-text review link
Check out our fully validated human Endostatin ELISA – developed and manufactured by Biomedica.
– For serum, plasma, and urine samples
– Easy – results in 4.5 h with only 20µl sample / well
– Fully validated assay according to international quality guidelines
Also available: Mouse/Rat Endostatin ELISA – only 5µl sample volume required
Related ELISA kits
Sclerostin, Angiopoietin-2, FGF23, IL-6
Abstract
Endostatin, a protein derived from the cleavage of collagen XVIII by the action of proteases, is an endogenous inhibitor known for its ability to inhibit proliferation and migration of endothelial cells, angiogenesis, and tumor growth. Angiogenesis is defined as the formation of new blood vessels from pre-existing vasculature, which is crucial in many physiological processes, such as embryogenesis, tissue regeneration, and neoplasia. Summary: Increasing evidence shows that dysregulation of angiogenesis is crucial for the pathogenesis of renal and cardiovascular diseases. Endostatin plays a pivotal role in the regulation of angiogenesis. Recent studies have provided evidence that circulating endostatin increases significantly in patients with kidney and heart failure and may also contribute to disease progression. Key Message: In the current review, we summarize the latest findings on preclinical and clinical studies analyzing the impact of endostatin on renal and cardiovascular diseases.
Related publications
- Endostatin predicts mortality in patients with acute dyspnea – A cohort study of patients seeking care in emergency departments. Carlsson AC, Wessman T, Larsson A, Leijonberg G, Tofik R, Ärnlöv J, Melander O, Ruge T. Clin Biochem. 2020. 75:35-39.
- Endostatin Is an Independent Risk Factor of Graft Loss after Kidney Transplant. Chu C, Hasan AA, Gaballa MMS, Zeng S, Xiong Y, Elitok S, Krämer BK, Hocher B. Am J Nephrol. 2020;51(5):373-380.
- Endostatin in chronic kidney disease: Associations with inflammation, vascular abnormalities, cardiovascular events and survival. Kanbay M, Afsar B, Siriopol D, Unal HU, Karaman M, Saglam M, Gezer M, Taş A, Eyileten T, Guler AK, Aydin İ, Oguz Y, Tarim K, Covic A, Yilmaz MI. Eur J Intern Med. 2016. 33:81-7.
- Detection of pro angiogenic and inflammatory biomarkers in patients with CKD. Jalal D, Sanford B, Renner B, Ten Eyck P, Laskowski J, Cooper J, Sun M, Zakharia Y, Spitz D, Dokun A, Attanasio M, Jones K, Thurman JM. Sci Rep. 2021.11(1):8786.
Acute kidney injury (AKI) is an abrupt loss of kidney function and is independently associated with high mortality in critically ill patients. Endostatin, the C-terminal proteolytic fragment of collagen XVIII, is expressed during the progression of renal fibrosis. A team of researchers recently demonstrated that serial measurement of plasma endostatin has useful predictive value for 30-day mortality in AKI patients.
Read more: Prognostic value of dynamic plasma endostatin for the prediction of mortality in acute kidney injury: A prospective cohort study. Jia HM et al., J Int Med Res. 2020 48(7):300060520940856. Full text
Endostatin can reliably be measured by ELISA in human serum, plasma and urine samples. Only 20 µl of sample volume is required!
Endostatin ELISA Assay Highlights: https://www.bmgrp.com/product/cardiovascular/human-endostatin-elisa-biomedica/
• SPECIFIC – no cross-reactivity with COL15A1
• CONVENIENT – Assay range optimized for clinical samples
• RELIABLE – Validated according to international quality guidelines
• EASY – Results in 4,5 h, all reagents included
Check out the recently published graphical abstract for: Endostatin is an independent risk factor of graft loss after kidney transplant. Chu C et al., Am J Nephrol. 2020 Apr 22;51(5):373-380.
Biomedica’s FULLY VALIDATED human and mouse/rat Endostatin ELISAs
Human Endostatin can easily be measured by ELISA assay
√ for serum, plasma, and urine samples
√ SIMPLE analysis – results in 4.5 h
√ LOW SAMPLE VOLUME – only 20µl sample / well
√ HIGH QUALITY – fully validated assay according to ICH/FDA/EMEA
Also available:
Mouse/Rat Endostatin ELISA – only 5µl sample volume required
Researchers from Germany have identified the endothelial basement membrane biomarker endostatin that can better predict the risk of graft loss in kidney transplant recipients (KTRs) in a prospective observational cohort study with 574 maintenance KTRs (median follow-up 48 months).
“.. increased serum endostatin concentrations at baseline are independently associated with the risk of graft loss in prevalent KTRs. Its association with graft loss seems to be even stronger as compared to the established classical risk factors for graft loss: decreased GFR and increased urinary protein excretion.“
Endostatin is an independent risk factor of graft loss after kidney transplant. Chu C et al., Am J Nephrol. 2020 Apr 22;51(5):373-380.
Biomedica’s FULLY VALIDATED human and mouse/rat Endostatin ELISAs
Human Endostatin can easily be measured by ELISA assay
√ for serum, plasma, and urine samples
√ SIMPLE analysis – results in 4.5 h
√ LOW SAMPLE VOLUME – only 20µl sample / well
√ HIGH QUALITY – fully validated assay according to ICH/FDA/EMEA
Also available:
Mouse/Rat Endostatin ELISA – only 5µl sample volume required
Rat/Mouse Endostatin ELISA highlights:
Human endostatin ELISA highlights:
Kidney disease is estimated to affect more than 800 million people worldwide (1). Taking action for prevention, early diagnosis and treatment can reduce the risk and the burden of kidney disease.
Role of the kidneys, kidney disease and risk factors
Kidneys are vital organs that regulate fluid balance, blood pressure and produce hormones that stimulate the production of red blood cells . Kidney disease is a condition in which kidneys lose their ability to effectively filter waste products and excess fluids from the blood. Kidney disease commonly leads to a decline in kidney function that may lead to kidney failure, characterized by the complete loss of kidney function. At this stage dialysis or kidney transplantation become the only treatment option.
Kidney problems can emerge suddenly (acute) or gradually over time (chronic). Various conditions, diseases and medications can contribute to acute and chronic kidney problems. Chronic kidney disease (CKD) is characterized by a prolonged period of kidney abnormalities that last for more than three months (2), whereas acute kidney disease – acute kidney injury (AKI) is characterized by a sudden loss of excretory kidney function (3).
Other forms of kidney disease include polycystic kidney disease (PKD) a genetic disorder that leads to kidney enlargement and impaired kidney function over time and glomerulonephritis (GN). GN is a group of diseases characterized by inflammation of the glomeruli, the filtration units of the kidney (4).
The most common risk factors for the development and progression of CKD are diabetes and high blood pressure. Managing blood sugar and blood pressure can help keep kidneys healthy. Other risk factors of CKD include heart disease, obesity, family history and genetic background as well as age, smoking and nutrition (5).
Consequences of kidney disease include heart disease, high blood pressure, bone and mineral disorders, and anemia (6).
Keep Your Kidneys Healthy
Regular exercise, weight control, a balanced diet (7) and sufficient fluid intake are only some of the ways to keep your kidney healthy.
World Kidney Day – about kidney health download here and check out the 6-Step Guide to Protecting Kidney Health here .
BIOMEDICA – Biomarker ELISA kits for clinical research in kidney disease
- HIGH QUALITY ASSAYS – Fully validated according to international quality guidelines
- TRUSTED – Widely cited in over 1500 publications
ELISA kits for: FGF23 (Fibroblast growth factor 23), Vanin-1, Endostatin, Sclerostin, Osteoprotegerin (OPG), Angiopoietin-2 (ANG-2), IL-6 (Interleukin-6) , VEGF (Vascular Endothelial Growth Factor)
Check out our brochure on Biomarkers in Clinical Nephrology
complete ready to use ELISA kits
Literature
- Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). Kovesdy CP. 2022 Apr;12(1):7-11. doi: 10.1016/j.kisu.2021.11.003. Epub 2022 Mar 18. PMID: 35529086; PMCID: PMC9073222.
- Chronic Kidney Disease Diagnosis and Management: A Review. Chen TK, Knicely DH, Grams ME. JAMA. 2019 Oct 1;322(13):1294-1304. doi: 10.1001/jama.2019.14745. PMID: 31573641; PMCID: PMC7015670.
- Acute kidney injury. Kellum JA, Romagnani P, Ashuntantang G, Ronco C, Zarbock A, Anders HJ. Nat Rev Dis Primers. 2021 Jul 15;7(1):52. doi: 10.1038/s41572-021-00284-z. PMID: 34267223.
- Glomerulonephritis: immunopathogenesis and immunotherapy. Anders HJ, Kitching AR, Leung N, Romagnani P.Nat Rev Immunol. 2023 Jul;23(7):453-471. doi: 10.1038/s41577-022-00816-y. Epub 2023 Jan 12. PMID: 36635359; PMCID: PMC9838307.
- Risk factors for chronic kidney disease: an update. Kazancioğlu R Kidney Int Suppl (2011). 2013 Dec;3(4):368-371. doi: 10.1038/kisup.2013.79. PMID: 25019021; PMCID: PMC4089662.
- Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia. Charytan DM, Fishbane S, Malyszko J, McCullough PA, Goldsmith D Am J Kidney Dis. 2015 Aug;66(2):196-205. doi: 10.1053/j.ajkd.2014.12.016. Epub 2015 Feb 26. PMID: 25727384; PMCID: PMC4516683.
- The Effect of Diet on the Survival of Patients with Chronic Kidney Disease. Rysz J, Franczyk B, Ciałkowska-Rysz A, Gluba-Brzózka A.Nutrients. 2017 May 13;9(5):495. doi: 10.3390/nu9050495. PMID: 28505087; PMCID: PMC5452225.
Chronic kidney disease is a progressive condition that affects >10% of the general population worldwide (1). Current clinical biomarkers prove effective at advanced stages of renal impairment, limiting the timely initiation of potentially successful therapeutic interventions. There is an unmet need for more refined biomarkers capable of detecting CKD at earlier stages, thereby enhancing the prospects for patients’ outcomes.
In the last decade, the advancement in the fields of genomics, proteomics, and metabolomics have led to the identification of potential biomarker candidates that may offer important diagnostic and prognostic information in patients suffering from kidney diseases (2).
Among the current established biomarkers such as serum creatinine, albuminuria, and proteinuria, novel biomarkers for kidney diseases could potentially provide additional prognostic information. They could help to predict treatment response in various clinical settings such as acute kidney injury, transplant rejection or glomerulopathies (2).
Emerging Biomarkers in Kidney Disease
Biomedica offers a range of ELISA assay kits to reliably detect biomarkers in blood samples of patients with kidney diseases.
Endostatin, Vanin-1, Periostin, FGF23, IL-6 and more…
Complete ready-to use ELISA kits
ENDOSTATIN – a potential biomarker of renal fibrosis, chronic kidney disease (CKD), prognostic marker in acute kidney injury (AKI)
Endostatin is an extracellular matrix protein which is expressed in patients during the progression of renal fibrosis. The significant increase of serum Endostatin levels may be due to the enhanced degradation of the extracellular matrix in patients with chronic kidney disease (3, 4). Endostatin has also been studied as a prognostic marker in patients with acute kidney injury (AKI) (5) and is independently associated with incident cardiovascular events in CKD patients (6).
Endostatin can reliably be quantified in serum, plasma and urine samples:
- Endostatin ELISA | BI-20742
- Endostatin ELISA (Mouse/Rat) | BI-20742MR (7)
VANIN-1 – a potential biomarker of acute kidney injury and drug induced renal injury
Vascular non-inflammatory molecule-1 (Vanin-1) is highly expressed in the kidney (8) and has been proposed as a marker in acute kidney injury and drug induced renal injury (9). Vanin-1 has been identified as a marker of kidney damage as shown n a rat model of type 1 diabetic nephropathy (10).
Urinary Vanin-1 has been investigated in children with renal fibrosis (11) and as a predictor of acute pyelonephritis in young children with urinary tract infection (12). A recent study investigated the role of urinary Vanin-1 in kidney transplant recipients (13).
Vanin-1 can easily be measured with a conventional ELISA assay:
- Vanin-1 (urine) ELISA | BI-VAN1U
- Vanin-1 ELISA (Mouse/Rat) ELISA | BI-VAN1MR
PERIOSTIN – a potential early biomarker of renal tubular injury
Periostin is a matricellular protein that is involved in tissue remodeling and wound healing. Studies have demonstrated that the expression of Periostin in the kidney correlates with the degree of interstitial fibrosis and a decline in kidney function (15). Elevated urine Periostin levels were found in patients with type 2 diabetes which were present before the onset of microaluminuria. The authors proposed that urinary Periostin could be an early biomarker of renal tubular injury (16).
Periostin can reliably be measured in serum, plasma, and urine samples with a fully validated ELISA assay (17).
- Periostin ELISA | BI-20422
- Periostin ELISA (Mouse/Rat) | BI-20433MR
FGF23 – a potential early biomarker cardiovascular events in patients with renal-cardiovascular disease
Fibroblast growth factor 23 (FGF23) is an endocrine hormone that regulates phosphate homeostasis by modulating renal phosphate reabsorption in the kidney. Circulating FGF23 increases with declining kidney function and high FGF23 and phosphate levels are related to cardiovascular disease and mortality (18, 19).
IL-6 – a biomarker of inflammation
Interleukin-6 (IL-6) is a cytokine that plays a crucial role in inflammation and in the regulation of immune response. It is a signaling molecule that is involved in various physiological processes, including the activation of immune cells and the coordination of responses to infections or injury. IL-6 is implicated in diseases where inflammation is a prominent feature (20).
- IL-6 ELISA | BI-IL6
- HIGHLY SENSITIVE – measurable values in serum and plasma samples
- EASY – ready to use calibrators and controls
Biomedica Immunoassays
Literature
- Epidemiology of chronic kidney disease: an update 2022. Kovesdy CP. Kidney Int Suppl (2011). 2022. 12(1):7-11. doi: 10.1016/j.kisu.2021.11.003. PMID: 35529086; PMCID: PMC9073222.
- Emerging Biomarkers for Early Detection of Chronic Kidney Disease. Mizdrak M, Kumrić M, Kurir TT, Božić J. J Pers Med. 2022. 12(4):548. doi: 10.3390/jpm12040548. PMID: 35455664.
- A defective angiogenesis in chronic kidney disease. Futrakul N, Butthep P, Laohareungpanya N, Chaisuriya P, Ratanabanangkoon K. Ren Fail. 2008. 30(2):215-7. doi: 0.1080/08860220701813335. PMID: 18300124.
- Endostatin in Renal and Cardiovascular Diseases. Li M, Popovic Z, Chu C, Krämer BK, Hocher B., Kidney Dis (Basel). 2021.9;7(6):468-481. doi: 10.1159/000518221. PMID: 34901193.
- Prognostic value of dynamic plasma endostatin for the prediction of mortality in acute kidney injury: A prospective cohort study. Jia HM, Zheng Y, Han Y, Ma WL, Jiang YJ, Zheng X, Guo SY, Zhang TE, Li WX., J Int Med Res. 2020. 48(7):300060520940856. PMID: 32691651.
- Endostatin in chronic kidney disease: Associations with inflammation, vascular abnormalities, cardiovascular events and survival. Kanbay M, Afsar B, Siriopol D, Unal HU, Karaman M, Saglam M, Gezer M, Taş A, Eyileten T, Guler AK, Aydin İ, Oguz Y, Tarim K, Covic A, Yilmaz MI. Eur J Intern Med. 2016. 33:81-7. doi: 10.1016/j.ejim.2016.06.033. PMID: 27394925.
- Validation of an enzyme-linked immunosorbent assay (ELISA) for quantification of endostatin levels in mice as a biomarker of developing glomerulonephritis. Wallwitz J, Aigner P, Gadermaier E, Bauer E, Casanova E, Bauer A, Stoiber D. PLoS One. 2019. 14(8):e0220935. doi: 10.1371/journal.pone.0220935. PMID: 31404120.
- Chemical biology tools to study pantetheinases of the vanin family. Schalkwijk, J, Jansen, P. Biochem Soc Trans. 2014. 42, 1052–1055.
- Urinary Vanin-1 As a Novel Biomarker for Early Detection of Drug-Induced Acute Kidney Injury. Hosohata K et al.J Pharm Exp Ther. 2012. 341, 656–662.
- Proteomic identification of vanin-1 as a marker of kidney damage in a rat model of type 1 diabetic nephropathy. Fugmann T et al., Kidney Int. 2011. 80, 272–281.
- The Usefulness of Vanin-1 and Periostin as Markers of an Active Autoimmune Process or Renal Fibrosis in Children with IgA Nephropathy and IgA Vasculitis with Nephritis-A Pilot Study. Mizerska-Wasiak M, Płatos E, Cichoń-Kawa K, Demkow U, Pańczyk-Tomaszewska M. J Clin Med. 2022. 11(5):1265. doi: 10.3390/jcm11051265. PMID: 35268356.
- Urinary vanin-1 for predicting acute pyelonephritis in young children with urinary tract infection: a pilot study. Krzemień G, Pańczyk-Tomaszewska M, Górska E, Szmigielska A. Biomarkers. 2021. 26(4):318-324.
- Urinary vanin-1, tubular injury, and graft failure in kidney transplant recipients. Alkaff FF, Kremer D, Niekolaas TM, van den Born J, Rimbach G, Tseng TL, Berger SP, Bakker SJL, de Borst MH. Sci Rep. 2024. 4(1):2283. doi: 10.1038/s41598-024-52635-x. PMID: 38280883.
- Development of an immunoassay that reveals altered uninary Vanin-1 in human with kidney disease. Wallwitz, J., Eichinger, B., Berg, G., Gadermaier, E., Himmler, G. 2018. Nephrology Dialysis Transplantation, Volume 33, Issue suppl_1, Page i126.
- Periostin in the Kidney. Wallace DP et al., Adv Exp Med Biol. 2019, 1132:99-112.
- Periostin as a tissue and urinary biomarker of renal injury in type 2 diabetes mellitus. Satirapoj B et al., PLoS One. 2015, 17;10(4):e0124055.
- Characterization of a sandwich ELISA for the quantification of all human periostin isoforms. Gadermaier E et al., J Clin Lab Anal. 2018, 32(2):e22252.
- Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Ärnlöv J, Carlsson AC, Sundström J, Ingelsson E, Larsson A, Lind L, Larsson TE. Kidney Int. 2013. 83(1):160-6. doi: 10.1038/ki.2012.327. PMID: 22951890.
- Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. Udell JA, Morrow DA, Jarolim P, Sloan S, Hoffman EB, O’Donnell TF, Vora AN, Omland T, Solomon SD, Pfeffer MA, Braunwald E, Sabatine MS. J Am Coll Cardiol. 2014. 10;63(22):2421-8, doi: 10.1016/j.jacc.2014.03.026. PMID: 24727254; PMCID: PMC4213068.
- Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome. Batra G, Ghukasyan Lakic T, Lindbäck J, Held C, White HD, Stewart RAH, Koenig W, Cannon CP, Budaj A, Hagström E, Siegbahn A, Wallentin L; STABILITY Investigators. JAMA Cardiol. 2021. 6(12):1440-1445. doi: 10.1001/jamacardio.2021.3079. PMID: 34431970; PMCID: PMC8387946.
When using an ELISA assay, it is important to ensure that the results are specific, accurate, sensitive, and reproducible. The ELISA assay reliability varies among kit suppliers, so choosing the “right” ELISA requires careful consideration. Access to the assay´s validation data before making a choice may be helpful.
ELISA Assay Reliability
At BIOMEDICA we take pride in developing and manufacturing our ELISA kits following a stringent manufacturing and quality control process, that enables us to maintain consistent and reproducible outcomes with every lot we produce.
At Biomedica we develop and manufacture our ELISA assays with care
All BIOMEDICA kits are fully validated and come with sample data for healthy human subjects, ready-to-use standards and controls. We supply our kits with color-coded vials, and some of the reagents are “colorful” as well, to make the kits easy to use and to avoid possible pipetting errors, To increase transparency, we publish the validation data of every ELISA assay kit on our website.
BIOMEDICA´s QUALITY GUIDELINES
AT BIOMEDICA, our goal is to supply reliable and well-validated ELISA kits for your research.
Here is how we ensure product excellence:
- Optimization: we diligently optimize all Biomedica assay to guarantee reliability, sensitivity, and precision.
- Validation: our kits undergo an extensive validation process in accordance with international quality guidelines (FDA, EMA, and ICH), ensuring the kits accuracy and efficiency.
- Expert Team: our dedicated team consists of highly qualified scientists, many with doctorate-level education and industry training. Our team has extensive research experience and contributes to the development, production, and customer service aspects of our products.
- Quality Management: Biomedica adheres to the ISO 9001: 2015 certified quality management system in our manufacturing process, ensuring consistent and high-quality products.
With these measures in place, we are committed to deliver ELISA assays that meet the highest standards of performance and reliability.
Learn more: https://www.bmgrp.com/quality
Related literature
Interference in ELISA. Matson RS. 2023. Methods Mol Biol. 2612:91-99. doi: 10.1007/978-1-0716-2903-1_7. PMID: 36795361.
Abstract
ELISA is a well-established technique used worldwide to quantify analytes present in a diverse milieu of biological samplings. It is especially important to clinicians who rely on the accuracy and precision of the test to administer patient care. Those results are to be held with great scrutiny since the assay is subject to error caused by interfering substances found in the sample matrix. In this chapter, we examine the nature of such interferences and discuss approaches to identify and offer remedies to remove the interference and validate the assay.
Validation of an enzyme-linked immunosorbent assay (ELISA) for quantification of endostatin levels in mice as a biomarker of developing glomerulonephritis. Wallwitz J, Aigner P, Gadermaier E, Bauer E, Casanova E, Bauer A, Stoiber D. 2019. PLoS One. 14(8):e0220935. doi: 10.1371/journal.pone.0220935. PMID: 31404120; PMCID: PMC6690585.
Abstract
Endostatin, the C-terminal fragment of type XVIII collagen, was shown to be one of the most potent endothelial cell-specific inhibitors of angiogenesis. As altered circulating endostatin concentration is associated with impaired kidney function, new tools for measuring endostatin in rodents may be helpful to further investigate and understand its role within kidney disease progression. A novel and commercially available ELISA for the quantification of mouse and rat endostatin was developed and validated according to international quality guidelines including the parameters specificity, robustness, accuracy, dilution linearity, precision, limit of detection (LOD) and lower limit of quantification (LLOQ). Endostatin and blood urea nitrogen (BUN) concentration were measured in mice with a glomerulonephritis phenotype. The validation revealed that within the range of 0.5-32 nmol/L the immunoassay is robust and highly specific for the measurement of rodent endostatin with high sensitivity (LOD 0.24 nmol/L, LLOQ 0.5 nmol/L) and good reproducibility (intra- and inter-assay CV <10%). Also accuracy and dilution linearity were within the range of acceptance. BCL2 transgenic and ETV6/RUNX1;BCL2 double transgenic mice develop a glomerulonephritis phenotype over time, which was displayed by staining of kidney sections. Even before full manifestation of disease serum endostatin concentration rises significantly, whereas BUN levels just slightly increase. This newly developed and commercially available ELISA provides a reliable and accurate tool for the quantification of mouse and rat endostatin and may give new perspectives in the investigation of the role of endostatin as an important and early biomarker for reduced kidney function. Measurement of endostatin concentration is recommended to be used as a superior biomarker for chronic kidney disease compared to BUN.
Practical Guide to Immunoassay Method Validation. Andreasson U et al. 2015. Front Neurol. 19;6:179. doi: 10.3389/fneur.2015.00179. PMID: 26347708; PMCID: PMC4541289.
World Kidney Day – March 9, 2023 – raising awareness of the importance of our kidneys
Around 1 in 10 people suffer from chronic kidney disease (CKD), with more than 800 million individuals being affected worldwide. CKD is a progressive disease in which the kidneys gradually lose their function over time. If detected early, medication and changes in lifestyle may help to prevent or slow down CKD progression.
What are the risk factors for CKD?
Older age (+60 years), diabetes, high blood pressure, heart disease, obesity and some medications are some known risk factors for kidney disease.
How can we keep our kidneys healthy?
Nutrition, exercise, sufficient fluid intake are only some examples on how to keep our kidneys healthy. Valuable information can be found on the following websites :
“The International Society of Nephrology – ISN”
“International Federation of Kidney Foundations – IFKF”
BIOMEDICA – Biomarker ELISA kits for clinical research in kidney disease
check out our Brochure – Biomarkers in Clinical Nephrology
ROBUST & RELIABLE ASSAYS
- Fully validated according to international quality guidelines
- Widely cited in over 1500 publications
FGF23 (Fibroblast growth factor 23) Vanin-1, Endostatin, Sclerostin, Osteoprotegerin, Angiopoietin-2, IL-6, VEGF
Biomedica Quality ELISA kits
LITERATURE
Plant-based diets for prevention and management of chronic kidney disease. Joshi S, Hashmi S, Shah S, Kalantar-Zadeh K. Curr Opin Nephrol Hypertens. 2020 Jan;29(1):16-21. doi: 10.1097/MNH.0000000000000574. PMID: 31725014.
Abstract
Purpose of review: Plant-based diets have been used with growing popularity for the treatment of a wide range of lifestyle-related diseases, including diabetes, hypertension, and obesity. With the reinvigoration of the dietary management of chronic kidney disease (CKD) and the use of low protein diets for secondary prevention of CKD to delay or prevent dialysis therapy, there is an increasing interest in the potential role of plant-based diets for these patients.
Recent findings: Recently, a body of evidence related to the role of plant-based diets in preventing CKD has reemerged. Several observational studies have shown that red and processed meat have been associated with increased risk of CKD as well as faster progression in those with preexisting CKD. In several substitution analyses, replacement of one serving of red and/or processed meat has been linked with sizable reductions in CKD risk. Although limited, experimental trials for the treatment of metabolic acidosis in CKD with fruits and vegetables show outcomes comparable to oral bicarbonate. The use of plant-based diets in CKD may have other benefits in the areas of hypertension, weight, hyperphosphatemia, reductions in hyperfiltration, and, possibly, mortality. The risk of potassium overload from plant-based diets appears overstated, mostly opinion-based, and not supported by the evidence. Plant-based diets are generally well tolerated and provide adequate protein intake, including essential amino acids as long as the diet is correctly implemented.
Summary: Plant-based diets should be recommended for both primary and secondary prevention of CKD. Concerns of hyperkalemia and protein inadequacy related to plant-based diets may be outdated and unsupported by the current body of literature. Healthcare providers in general medicine and nephrology can consider plant-based diets as an important tool for prevention and management of CKD.
Exercise and Kidney Disease Prevention: Walk This Way. Seliger S, Weiner DE. Am J Kidney Dis. 2022 Oct;80(4):552-554. doi: 10.1053/j.ajkd.2022.07.001. Epub 2022 Jul 21. PMID: 35872228.
Raising awareness, screening and prevention of chronic kidney disease: It takes more than a village. Hsiao LL. Nephrology (Carlton). 2018 Oct;23 Suppl 4:107-111. doi: 10.1111/nep.13459. PMID: 30298651.
Abstract
Chronic kidney disease (CKD) is a major public health problem worldwide. Its prevalence and incidence are increasing, particularly among the ethnic minority populations. Diabetes, hypertension and obesity have been the three major aetiologies for CKD in all developed countries. While diabetes and hypertension remain the major causes of CKD in developing countries, environmental pollution, pesticides, water, analgesic abuse and herbal medications are common causes in these regions. Rapid urbanization and globalization are thought to be the contributing factors to rising prevalence and incidents of CKD. Despite the rising prevalence of CKD, disease awareness remains profoundly low. Worldwide, only 6% of the general population and 10% of the high-risk population are aware of their CKD statuses. Health screenings have been shown to be effective in improving the incidence of ESRD. However, currently there is no effective tool to assess and evaluate the awareness objectively.
Microbiome-metabolome reveals the contribution of gut-kidney axis on kidney disease. Chen YY, Chen DQ, Chen L, Liu JR, Vaziri ND, Guo Y, Zhao YY. J Transl Med. 2019 Jan 3;17(1):5. doi: 10.1186/s12967-018-1756-4. PMID: 30602367; PMCID: PMC6317198.
February is “Heart Month” raising awareness about heart disease. Biomarker research has revolutionized on how heart diseases are diagnosed and treated. Ongoing research on newer exploratory protein biomarkers may shed light into the complex mechanisms that drive the disease process.
Novel Biomarkers for Heart Disease
BIG ENDOTHELIN-1, ENDOSTATIN, FGF23, LRG
Big Endothelin-1 (Big ET-1) is a vasoconstrictor peptide and is the precursor of Endothelin-1 (ET-1) the biologically active form. Elevated concentrations provide an independent indicator of heart failure in congestive heart disease (1). Big ET-1 has a longer half-life than ET-1 and circulates in equimolar amounts as ET-1, making it a more reliable biomarker.
Endostatin is a degradation product of collagen XVIII and is an extracellular matrix protein. Endostatin plays an essential role in the pathogenesis of chronic kidney and heart diseases (2). A study in two community-based cohorts of elderly showed an association of high serum endostatin levels with left ventricular dysfunction and an increased heart failure risk (3).
Fibroblast growth factor-23 (FGF23) is a hormone that regulates phosphate metabolism. FGF23 has been suggested as a novel candidate biomarker of cardiovascular risk. High circulating FGF23 levels have been associated with adverse cardiovascular outcomes such as heart failure and arrhythmias (4).
Leucine-riche alpha-2-glyoprotein (LRG) is a secreted protein that plays an important role in pathogenic ocular neovascularization. LRG is also involved in multiple conditions including cardiovascular disease, diabetes, inflammatory disorders, and cancer. A recent study demonstrated that LRG accurately identify patients with heart failure stronger than BNP, independent of age, sex, and creatinine (5, 6).
NOVEL BIOMARKERS FOR HEART DISEASE
Biomedica offers a range of top quality ELISA kits for your clinical & preclinical research.
-Big Endothelin-1 (#BI-20082H)
-Endostatin (#BI-20742)
-Endostatin mouse/rat (#BI-20742MR)
-FGF23 intact (#BI-20700)
-FGF23 c-terminal (#BI-20702)
-LRG (#BI-LRG)
|
LITERATURE
- Plasma concentration of big endothelin-1 and its relation with plasma NT-proBNP and ventricular function in heart failure patients. Rivera M et al., Rev Esp Cardiol. 2005; 58(3):278-84.
- Endostatin in Renal and Cardiovascular Diseases. Li M et al., Kidney Dis. 2021; 9;7(6):468-481.
- Circulating endostatin and the incidence of heart failure. Ruge T et al., 2018; 52(5):244-249.
- Fibroblast Growth Factor 23 and Long-Term Cardiac Function: The Multi-Ethnic Study of Atherosclerosis. Patel RB et al., Cardiovasc Imaging. 2020; 13(11):e011925.
- Proteomic analysis of coronary sinus serum reveals leucine-rich α2-glycoprotein as a novel biomarker of ventricular dysfunction and heart failure. Watson CJ et al., Circ Heart Fail. 2011; 4(2):188-97.
- Serum biomarker discovery related to pathogenesis in acute coronary syndrome by proteomic approach Shin M et al.,Biosci Rep. 2021; 25;41(6):BSR20210344.
Discover Biomedica Biomarker ELISA Kits for Biomarkers in Bone-Kidney-Heart diseases.
Developed & manufactured by Biomedica` Immunoassays
Austrian Quality!
√ WIDELY CITED in +1500 publications
Discover Biomedica Biomarker ELISA Kits
Biomarker Assays
√ Natriuretic Peptides NT-proBNP, NT-proANP (for human and rat samples), NT-proCNP
√ Endothelins Big Endothelin-1
√ Wnt inhibitors Sclerostin, Dickkopf-1 (DKK-1)
√ Bone metabilism Osteoprotegerin (OPG), soluble free RANKL (sRANKL)
√ Nephrology & transplant Fibroblast growth factor 23 (FGF23 c-terminal and FGF23 intact),
Endostatin, Angiopoietin-2 (human, mouse and rat) , Neuropilin-1,
Vanin-1 urine (human, mouse and rat), anti-C4d antibody
RELATED CITATIONS
Big Endothelin-1 (BigET-1)
Plasma Big Endothelin-1 Level Predicted 5-Year Major Adverse Cardiovascular Events in Patients With Coronary Artery Ectasia. Cai Z, Wang H, Yuan S, Yin D, Song W, Dou K.Front Cardiovasc Med. 2021 Nov 29;8:768431. doi: 10.3389/fcvm.2021.768431. PMID: 34912865; PMCID: PMC8667227.
Abstract
Background: Coronary artery ectasia (CAE) is found in about 1% of coronary angiography and is associated with poor clinical outcomes. The prognostic value of plasma big Endothelin-1 (ET-1) in CAE remains unknown. Methods: Patients with angiographically confirmed CAE from 2009 to 2015, who had big ET-1 data available were included. The primary outcome was 5-year major adverse cardiovascular events (MACE), defined as a component of cardiovascular death and non-fatal myocardial infarction (MI). Patients were divided into high or low big ET-1 groups using a cut-off value of 0.58 pmol/L, according to the receiver operating characteristic curve. Kaplan-Meier method, propensity score method, and Cox regression were used to assess the clinical outcomes in the 2 groups. Results: A total of 992 patients were included, with 260 in the high big ET-1 group and 732 in the low big ET-1 group. At 5-year follow-up, 57 MACEs were observed. Kaplan-Meier analysis and univariable Cox regression showed that patients with high big ET-1 levels were at increased risk of MACE (9.87 vs. 4.50%; HR 2.23, 95% CI 1.32-3.78, P = 0.003), cardiovascular death (4.01 vs. 1.69%; HR 2.37, 95% CI 1.02-5.48, P = 0.044), and non-fatal MI (6.09 vs. 2.84%; HR 2.17, 95% CI 1.11-4.24, P = 0.023). A higher risk of MACE in the high big ET-1 group was consistent in the propensity score matched cohort and propensity score weighted analysis. In multivariable analysis, a high plasma big ET-1 level was still an independent predictor of MACE (HR 1.82, 95% CI 1.02-3.25, P = 0.043). A combination of high plasma big ET-1 concentrate and diffuse dilation, when used to predict 5-year MACE risk, yielded a C-statistic of 0.67 (95% CI 0.59-0.74). Conclusion: Among patients with CAE, high plasma big ET-1 level was associated with increased risk of MACE, a finding that could improve risk stratification.
Sepsis is a life-threatening organ dysfunction and has become the main cause of in-hospital death in severe trauma patients. It is caused by an extreme response of the body to an infection. The early recognition of sepsis is critical for timely initiation of treatment and new biomarkers may help for early diagnosis. Researchers recently investigated the use of Vanin-1 as a possible predictive biomarker of traumatic sepsis. The study demonstrated that Vanin-1 increased among trauma patients and was independently associated with the risk of sepsis, especially in the first 3 days after injury.
View abstract: Plasma Vanin-1 as a Novel Biomarker of Sepsis for Trauma Patients: A Prospective Multicenter Cohort Study. Lu H et al. , J Infect Dis Ther. 2021. 10(2):739-751.
Abstract:
Introduction: Vanin-1 plays a pivotal role in oxidative stress and the inflammatory response. However, its relationship with traumatic sepsis remains unknown. The aim of our study was to evaluate whether plasma vanin-1 could be used for the early prediction of traumatic sepsis.
Methods: In this three-stage prospective cohort study, severe trauma patients admitted from January 2015 to October 2018 at two hospitals were enrolled. Plasma vanin-1 levels were measured by enzyme-linked immunosorbent assay (ELISA). The associations among variables and traumatic sepsis were identified by logistic regression models and the receiver operating characteristic (ROC) curve was analyzed to evaluate the diagnostic efficiency.
Results: A total of 426 trauma patients (22 in the discovery cohort, 283 in the internal test cohort, and 121 in the external validation cohort) and 16 healthy volunteers were recruited. The plasma vanin-1 of trauma patients was significantly higher than that of healthy volunteers (P < 0.05). Patients with sepsis had higher plasma vanin-1 than patients without sepsis in the discovery trauma cohort (P < 0.05). In the internal test cohort, plasma vanin-1 at day 1 after trauma was significantly associated with the incidence of sepsis (OR = 3.92, 95% CI 2.68-5.72, P = 1.62 × 10-12). As a predictive biomarker, vanin-1 afforded a better area under the curve (AUC) (0.82, 95% CI 0.77-0.87) than C-reaction protein (CRP) (0.62, 95% CI 0.56-0.68, P < 0.0001), procalcitonin (PCT) (0.66, 95% CI 0.60-0.71, P < 0.0001), and Acute Physiology and Chronic Health Evaluation II (APACHE II) (0.71, 95% CI 0.65-0.76, P = 6.70 × 10-3). The relevance was further validated in the external validation cohort (OR = 4.26, 95% CI 2.22-8.17, P = 1.28 × 10-5), with an AUC of 0.83 (95% CI 0.75-0.89). Vanin-1 could also improve the diagnostic efficiency of APACHE II (AUC = 0.85).
Conclusions: Our study demonstrated that plasma vanin-1 increased among trauma patients and was independently associated with the risk of sepsis. Vanin-1 might be a potential biomarker for the early prediction of traumatic sepsis.
Human VANIN -1 can reliably be measured in urine samples by ELISA
√ Optimized for human urine samples
√ Highly SPECIFIC and DEFINED characterized antibodies
√ RELIABLE rigorously validated according to FDA/ICH/EMEA guidelines
√ QUICK one-step ELISA
Related products:
Nephrology: FGF23, Endostatin, Anti C4d
Cardiology: NT-proBNP, Endothelins, proANP, NT-proCNP
First commercially available fully validated ELISA to reliably measure Vanin-1 in human urine samples from Biomedica.
Vanin-1 is a glycoprotein that is selectively expressed in renal tubular cells.
Urinary Vanin-1
- has as superior predictive value for drug induced AKI than KIM-1 or NGAL
- is a novel biomarker to detect and monitor the clinical course of obstructive nephropathy
Biomedica offers the FIRST fully validated VANIN-1 (urine) ELISA for reliable results
Try our VANIN-1 (urine) ELISA and contact us for your evaluation discount.
Related Literature & Findings:
Urinary Vanin-1 As a Novel Biomarker for Early Detection of Drug-Induced Acute Kidney Injury. Hosohata K et al., J Pharmoc Exp Therapeut, 2012; 656–62.
A Novel Biomarker for Acute Kidney Injury, Vanin-1, for Obstructive Nephropathy: A Prospective Cohort Pilot Study. Washino S. et al., Int J Mol Sci, 2019; 20, 4.
Pharmacological inhibition of Vanin-1 is not protective in models of acute and chronic kidney disease. Unterschemmann K, Ehrmann A, Herzig I, Andreevski AL, Lustig K, Schmeck C, Eitner F, Grundmann M. Am J Physiol Renal Physiol. 2021 Jan 1;320(1):F61-F73. doi: 10.1152/ajprenal.00373.2020. Epub 2020 Nov 16. PMID: 33196323.
Abstract
Oxidative stress is a key concept in basic, translational, and clinical research to understand the pathophysiology of various disorders, including cardiovascular and renal diseases. Although attempts to directly reduce oxidative stress with redox-active substances have until now largely failed to prove clinical benefit, indirect approaches to combat oxidative stress enzymatically have gained further attention as potential therapeutic strategies. The pantetheinase Vanin-1 is expressed on kidney proximal tubular cells, and its reaction product cysteamine is described to negatively affect redox homeostasis by inhibiting the replenishment of cellular antioxidative glutathione stores. Vanin-1-deficient mice were shown to be protected against oxidative stress damage. The aim of this study was to elucidate whether pharmacological inhibition of Vanin-1 protects mice from oxidative stress-related acute or chronic kidney injury as well. By studying renal ischemia-reperfusion injury in Col4α3-/- (Alport syndrome) mice and in vitro hypoxia-reoxygenation in human proximal tubular cells we found that treatment with a selective and potent Vanin-1 inhibitor resulted in ample inhibition of enzymatic activity in vitro and in vivo. However, surrogate parameters of metabolic and redox homeostasis were only partially and insufficiently affected. Consequently, apoptosis and reactive oxygen species level in tubular cells as well as overall kidney function and fibrotic processes were not improved by Vanin-1 inhibition. We thus conclude that Vanin-1 functionality in the context of cardiovascular diseases needs further investigation and the biological relevance of pharmacological Vanin-1 inhibition for the treatment of kidney diseases remains to be proven.
BI-VAN1U – human VANIN-1 ELISA Assay Highlights:
√ Optimized for human urine samples
√ Highly SPECIFIC and DEFINED characterized antibodies
√ RELIABLE rigorously validated according to FDA/ICH/EMEA guidelines
√ QUICK one-step ELISA
Related products:
Nephrology: FGF23, Endostatin, Anti C4d
Cardiology: NT-proBNP, Endothelins, proANP, NT-proCNP
ERA-EDTA 2018, May 24-27
Bella Center, Copenhagen, DK
ECTS 2018, May 26-29
VCC, Valencia, ES
Product Highlights:
bioactive Sclerostin ELISA
FGF23 (C-terminal) ELISA
Endostatin ELISA
soluble Semaphorin 4 D ELISA
total soluble Neuropilin-1 ELISA
Additional information on Biomedica’s Biomarker Assays:
Bone Metabolism
Cardiovascular
Nephrology
Biomedica Analytical Testing Service
Useful links:
ERA-EDTA 2018 Congress Website
Meet us at poster #P163 to learn about our C-terminal FGF23 ELISA and our nephrology product line!
From 27th-30th September, Biomedica will participate at the Annual Congress for German Nephrology taking place at the Estrel Convention Center in Berlin. The congress is hosted by the German Society for Nephrology (Deutsche Gesellschaft für Nephrologie, DGfN), which celebrates its 10th anniversary this year.
According to the DGfN, between four and six million Germans live with reduced kidney function. 80,000 of these patients are currently being treated with dialysis. Another 25,000 patients are under medical surveillance after a successful kidney transplant. Therapy for kidney diseases is cost-intensive; treatment for an average dialysis patient amounts to 40,000 Euros per year, amounting to 3 billion Euros health care costs annually. For more information go to http://www.die-nephrologen.de/fakten.html.
To ameliorate current treatment regimens and bring innovative technology to the clinic, the DGfN supports cooperation between ambulant and stationary clinicians and promotes the development of innovative and coordinated strategies to tackle the challenge of improving early diagnosis and long-term treatment of patients with kidney diseases.
One important aspect of improving outcomes is to stratify risk and detect diseases in an early stage. For this reason, Biomedica specialises in developing high-quality biomarker ELISAs for clinical research and application.
As our contribution to the scientific programme of the Kongress Für Nephrologie 2018, Biomedica will be presenting a poster about our C-terminal FGF-23 ELISA kit, a biomarker that has been linked to the clinical outcomes in both acute kidney injury and chronic kidney disease.
Dr. Annegret Bitzer, one of our Biomedica Product managers, is going to present the C-terminal FGF-23 poster (Poster #P163) on Friday 28th September from 2-3:30 pm, and will be happy to chat with you about the clinical significance of intact FGF-23 in kidney disease, as well as about the biomarkers in our innovative nephrology product line, which includes:
Human and mouse/rat Endostatin ELISAs
C-terminal FGF-23 ELISA
Bioactive Sclerostin ELISA
Osteoprotegerin ELISA
Total soluble Neuropilin-1 ELISA
Anti-C4d Antibodies
Coming soon:
Vanin-1 ELISA
intact FGF23 ELISA
We look forward to meeting you at the Congress!
Biomedica is happy to introduce its new brochure featuring biomarker ELISAs for clinical research of cancer diseases.
Click link for BIOMEDICA ONCOLOGY PRODUCT LEAFLET.
Detailed product information:
DKK-1 ELISA, BI-20413
OPG ELISA, BI-20403
free sRANKL ELISA, BI-20462
Sclerostin ELISA, BI-20492
bioactive Sclerostin ELISA, BI-20472
FGF23 ELISA, BI-20702
Periostin ELISA, BI-20433
Semaphorin 4D ELISA, BI-20405
Endostatin ELISA, BI-20742
total sNRP1 ELISA, BI-20409